publication . Article . 2021

Current trends in pediatric aggressive B-cell lymphomas treatment

Yu. S. Korkina; T. T. Valiev;
Open Access Russian
  • Published: 01 Jun 2021 Journal: Onkogematologiâ, volume 16, issue 2, pages 21-27 (issn: 1818-8346, Copyright policy)
  • Publisher: ABV-press
Nowadays due to modern risk-adapted treatment protocols high survival rates have been achieved in patients with aggressive B-cell lymphomas, even at stages III–IV these indicators overrun 90 %. Mainly these successes were associated with the inclusion of rituximab in the standard chemotherapy regimens. As the follow up period of the patients is lengthened, it has become clear that ongoing treatment is associated with the development of immediate and long-term adverse effects of chemoimmunotherapy. In Russia and the world, there are multicenter studies aimed at studying prognostic factors that make it possible to reduce single and/or total doses of chemotherapy d...
Persistent Identifiers
free text keywords: burkitt lymphoma, diffuse large b-cell lymphoma, primary mediastinal (thymic) large b-cell lymphoma, chemotherapy, rituximab, dose reduction, treatment, children, Diseases of the blood and blood-forming organs, RC633-647.5, Oncology, Hematology
Any information missing or wrong?Report an Issue